v3.26.1
Segment reporting - Schedule of Segment Performance (Details) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Disclosure of operating segments [line items]    
Revenue from contracts with customers $ 477,350 $ 390,359
Cost of sales (217,001) (181,736)
Gross profit 260,349 208,623
Other income 40,000 0
Research and development costs (123,828) (81,583)
Selling and marketing expenses (58,358) (48,973)
Manufacturing and distribution costs (28,713) (18,849)
General and administration costs (48,663) (47,723)
Other gains/(losses) (net) 5,575 (1,105)
Operating profit 46,362 10,390
Other (gains)/losses (net) (5,575) 1,105
Depreciation and amortization 11,155 9,585
Total segment adjusted EBITDA 76,492 47,943
Operating segments    
Disclosure of operating segments [line items]    
Revenue from contracts with customers 477,350 390,359
Inter-segment revenue 0 0
Cost of sales (217,001) (181,736)
Gross profit 260,349 208,623
Other income 40,000  
Research and development costs (123,828) (81,583)
Selling and marketing expenses (58,358) (48,973)
Manufacturing and distribution costs (28,713) (18,849)
General and administration costs (23,625) (20,435)
Other gains/(losses) (net) 2,259 (1,547)
Operating profit 68,084 37,236
Other (gains)/losses (net) (2,259) 1,547
Depreciation and amortization 10,667 9,160
Total segment adjusted EBITDA 76,492 47,943
Operating segments | Precision Medicine    
Disclosure of operating segments [line items]    
Revenue from contracts with customers 388,633 305,835
Inter-segment revenue 0 0
Cost of sales (134,600) (108,839)
Gross profit 254,033 196,996
Other income 0  
Research and development costs (54,482) (38,116)
Selling and marketing expenses (49,236) (40,886)
Manufacturing and distribution costs (6,625) (4,105)
General and administration costs (12,508) (11,317)
Other gains/(losses) (net) 1,195 (1,593)
Operating profit 132,377 100,979
Other (gains)/losses (net) (1,195) 1,593
Depreciation and amortization 707 2,074
Total segment adjusted EBITDA 131,889 104,646
Operating segments | Therapeutics    
Disclosure of operating segments [line items]    
Revenue from contracts with customers 0 3,994
Inter-segment revenue 0 0
Cost of sales 0 (108)
Gross profit 0 3,886
Other income 40,000  
Research and development costs (67,968) (43,868)
Selling and marketing expenses 0 (464)
Manufacturing and distribution costs (2,348) (1,710)
General and administration costs (2,215) (2,002)
Other gains/(losses) (net) 1,240 19
Operating profit (31,291) (44,139)
Other (gains)/losses (net) (1,240) (19)
Depreciation and amortization 149 117
Total segment adjusted EBITDA (32,382) (44,041)
Operating segments | Manufacturing Solutions    
Disclosure of operating segments [line items]    
Revenue from contracts with customers 88,717 80,530
Inter-segment revenue 57,543 33,761
Cost of sales (138,435) (103,485)
Gross profit 7,825 10,806
Other income 0  
Research and development costs (2,828) (2,664)
Selling and marketing expenses (9,122) (7,623)
Manufacturing and distribution costs (19,740) (13,034)
General and administration costs (8,902) (7,116)
Other gains/(losses) (net) (176) 27
Operating profit (32,943) (19,604)
Other (gains)/losses (net) 176 (27)
Depreciation and amortization 9,811 6,969
Total segment adjusted EBITDA (22,956) (12,662)
Inter-segment eliminations    
Disclosure of operating segments [line items]    
Revenue from contracts with customers 0 0
Inter-segment revenue (57,543) (33,761)
Cost of sales 56,034 30,696
Gross profit (1,509) (3,065)
Other income 0  
Research and development costs 1,450 3,065
Selling and marketing expenses 0 0
Manufacturing and distribution costs 0 0
General and administration costs 0 0
Other gains/(losses) (net) 0 0
Operating profit (59) 0
Other (gains)/losses (net) 0 0
Depreciation and amortization 0 0
Total segment adjusted EBITDA $ (59) $ 0